title: In vitro and in vivo silencing of the androgen receptor.
abstract: The androgen receptor (AR) plays a pivotal role in the progression of prostate cancer from the androgen-dependent to the castration-resistant state, making it a potential target for therapy. In this chapter, we describe the preparation and use of sublines of LNCaP and C4-2 human prostate cancer cells which have been engineered to stably express a doxycycline (DOX)-inducible AR shRNA in order to study the in vitro and in vivo effects of AR knockdown.
authors.affiliation: Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada. hcheng@prostatecentre.com
authors.forename: Helen
authors.initials: H
authors.lastname: Cheng
authors.forename: Eric
authors.initials: E
authors.lastname: Leblanc
authors.forename: Paul S
authors.initials: PS
authors.lastname: Rennie
mesh_terms: D000818:Animals; D001483:Base Sequence; D001681:Biological Assay; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003001:Cloning, Molecular; D004318:Doxycycline / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D055785:Gene Knockdown Techniques; D020868:Gene Silencing; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics; D057809:HEK293 Cells; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D011944:Receptors, Androgen / Q000235:genetics* / Q000378:metabolism*; D011995:Recombination, Genetic; D012097:Repressor Proteins / Q000187:drug effects / Q000235:genetics; D014158:Transcription, Genetic; D023041:Xenograft Model Antitumor Assays
chemical_list: D034741:RNA, Small Interfering; D011944:Receptors, Androgen; D012097:Repressor Proteins; C034811:tetracycline resistance-encoding transposon repressor protein; D004318:Doxycycline